226 related articles for article (PubMed ID: 21367600)
1. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
3. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
[TBL] [Abstract][Full Text] [Related]
4. Would general practitioners support a population-based colorectal cancer screening programme of faecal-occult blood testing?
Tong S; Hughes K; Oldenburg B; Del Mar C
Intern Med J; 2004; 34(9-10):532-8. PubMed ID: 15482265
[TBL] [Abstract][Full Text] [Related]
5. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
[TBL] [Abstract][Full Text] [Related]
6. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population.
Guittet L; Bouvier V; Mariotte N; Vallee JP; Arsène D; Boutreux S; Tichet J; Launoy G
Gut; 2007 Feb; 56(2):210-4. PubMed ID: 16891354
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer test use--Maryland, 2002-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
[TBL] [Abstract][Full Text] [Related]
9. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms.
Dancourt V; Lejeune C; Lepage C; Gailliard MC; Meny B; Faivre J
Eur J Cancer; 2008 Oct; 44(15):2254-8. PubMed ID: 18760592
[TBL] [Abstract][Full Text] [Related]
10. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
11. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
[TBL] [Abstract][Full Text] [Related]
12. Effects of communicating social comparison information on risk perceptions for colorectal cancer.
Lipkus IM; Klein WM
J Health Commun; 2006 Jun; 11(4):391-407. PubMed ID: 16720537
[TBL] [Abstract][Full Text] [Related]
13. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
14. Attitudes, knowledge and practice of CRC screening among GPs in Queensland.
Youl PH; Jackson C; Oldenburg B; Brown C; Dunn J; Aitken J
Aust Fam Physician; 2006 Jul; 35(7):547-50. PubMed ID: 16820832
[TBL] [Abstract][Full Text] [Related]
15. A population-based estimate of the extent of colorectal cancer screening in Ontario.
Rabeneck L; Paszat LF
Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
17. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
18. Screening colonoscopy and fecal occult blood testing practice patterns: a population-based survey of gastroenterologists.
Rossi F; Sosa JA; Aslanian HR
J Clin Gastroenterol; 2008; 42(10):1089-94. PubMed ID: 18936643
[TBL] [Abstract][Full Text] [Related]
19. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
Clarke P; Jack F; Carey FA; Steele RJ
Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
[TBL] [Abstract][Full Text] [Related]
20. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
